asco 2018 keynote189 - cisplatin or carboplatin with alimta & keytruda - practice changing approach?
Published 5 years ago • 1.8K plays • Length 11:29Download video MP4
Download video MP3
Similar videos
-
11:15
asco 2018 - keynote 042 - keytruda as a single agent compared to doublet chemotherapy for nsclc
-
6:27
asco 2018 - tarceva combined with carboplatin & alimta - given upfront - affect pace of disease?
-
7:54
keytruda combined with anti-vegf treatment:use in patients with advanced nsclc-asco lung review 2022
-
12:26
asco 2018 - potential showdown of two positive trials? keynote 407 and impower 131
-
3:34
asco 2018 - keynote 158 - keytruda in previously treated, now relapsing patients with sclc
-
7:35
asco 2018 - will taking mod to high dose steroids affect lung cancer pts on immunotherapy?
-
4:26
asco 2018 - dream study - chemo with imfinzi (durvalumab) for mesothelioma
-
2:52
asco 2018 - combining metformin with standard egfr therapy - is the jury still out
-
6:52
new data from asco 2017 on weekly cisplatin regimens
-
8:13
checkmate 816: combining chemo and opdivo - asco lung review 2022
-
9:11
asco 2018 - tarceva or tarceva with avastin as 1st line for egfr pos. nsclc vs. tagrisso or vizimpro
-
6:32
asco 2019 lung cancer round table - new cancer research: long term outcomes of pembrolizumab
-
7:26
new research: stage 1 nsclc - retrospective japanese data - asco 2019
-
13:44
gracecast-079_lung-cancer_challenging cases in lung cancer: unresectable locally advanced nsclc
-
10:39
gracecast - lcvl - can patients with an egfr mutation-positive advanced nsclc benefit from immunothe
-
8:38
gracecast-109_lung-cancer_asco 2012 lung cancer highlights: dr. mark socinski on paramount trial
-
4:14
case based panel discussion - egfr and high pdl1 what is the role of immunotherapy in treatment?
-
23:32
gracecast-077_lung-cancer_asco 2011 highlights - advanced/metastatic nsclc